Table 1.
Association of PD-L1 and PD-1 expression with histopathological parameters.
| PD-L1− | PD-L1+ | p value | PD-1− | PD-1+ | p value | |
|---|---|---|---|---|---|---|
| Patients | 677 | 61 | 682 | 56 | ||
| AJCC tumor stage | <0.001 | <0.001 | ||||
| pT1 | 475 (70.2) | 29 (47.5) | 471 (69.1) | 23 (41.1) | ||
| pT2 | 152 (22.5) | 11 (18) | 159 (23.3) | 11 (19.6) | ||
| ⩾pT3 | 50 (7.3) | 21 (34.4) | 52 (7.6) | 22 (39.3) | ||
| Tumor necrosis | 0.012 | 0.0185 | ||||
| No | 519 (76.7) | 38 (62.3) | 512 (75) | 34 (60.7) | ||
| Yes | 158 (23.3) | 23 (37.7) | 170 (25) | 22 (39.3) | ||
| Lymphovascular invasion | 0.037 | <0.001 | ||||
| No | 604 (89.2) | 49 (80.4) | 610 (89.4) | 41 (73.2) | ||
| Yes | 73 (10.8) | 12 (19.6) | 72 (10.6) | 15 (26.8) | ||
| Fuhrman grade | 0.237 | <0.001 | ||||
| ⩽2 | 386 (57) | 30 (49.2) | 392 (57.5) | 19 (33.9) | ||
| ⩾3 | 291 (43) | 31 (50.8) | 290 (42.5) | 37 (66.1) |
Bold values indicate statistical significance.
AJCC, American Joint Committee on Cancer; PD-1, programmed cell-death 1; PD-L1, programmed cell-death ligand 1.